Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAP score prediction of response to Octagam 5% in early relapsing multiple sclerosis
ISRCTN82177408Phase 3Completed
- Sponsor
- Octapharma
- Start
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of Human normal immunoglobulin G in multiple sclerosis (MS), sponsored by Octapharma. Started Jun 2013; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ISRCTN82177408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN82177408.